Zentalis Pharmaceuticals (ZNTL)

• Market cap: $352M
• 1 day: 1.43%
• 5 days: 3.56%
• 1 month: 4.87%
• 3 months: 21.03%
• 6 months: 123.98%
• Year to date: 261.31%
• 1 year: 251.06%
• 5 years: -90.73%
• 10 years: -78.66%
• Sector: Healthcare
• Industry: Biotechnology

About: Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Employees: 106